TY - JOUR
T1 - Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1
AU - Pediatric AIDS Clinical Trials Group 377 Study Team
AU - Krogstad, Paul A.
AU - Lee, Sophia
AU - Johnson, George
AU - Stanley, Kenneth
AU - Mc Namara, James
AU - Moye, John
AU - Aguayo, Rosaura
AU - Dieudonne, Arry
AU - Khoury, Margaret
AU - Mendez, Hermann
AU - Jackson, Brooks
AU - Wiznia, Andrew
AU - Ballow, Anita
AU - Aweeka, Francesca
AU - Rosenblatt, Howard Max
AU - Perdue, Lynette
AU - Frasia, Anne
AU - Jeremy, Rita
AU - Anderson, Martin
AU - Japour, Anthony
AU - Fields, Catherine
AU - Farnsworth, Angie
AU - Lewis, Ronald
AU - Schnittman, Steven
AU - Gigliotti, Maria
AU - Maldonaldo, Samuel
AU - Lane, Barbara
AU - Hernandez, Jaime E.
AU - Mohan, Kathleen
AU - Fikrig, S.
AU - Swindell, H. Moallem
AU - Mendez, H.
AU - Handelsman, E.
AU - Bergin, H.
AU - Aguayo, R.
AU - Figueroa, W. I.
AU - Reyes, E. J.
AU - Storm, D.
AU - Stephens, R.
AU - Palumbo, P.
AU - Kovacs, A.
AU - Khoury, M.
AU - Homans, J.
AU - Kairam, R.
AU - Bamji, M.
AU - Biernick, W.
AU - Dorio, K.
AU - Chin, M.
AU - Abrams, E. J.
N1 - Funding Information:
Financial support: Pediatric AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases; Pediatric/Perinatal HIV Clinical Trials Network of the National Institute of Child Health and Human Development; Abbott Laboratories; Agouron Pharmaceuticals; Boehringer-Ingelheim Pharmaceuticals; Bristol-Myers Squibb; and Glaxo-Wellcome. National Institute of Allergy and Infectious Diseases (grant AI-41110). P.K. is an Elizabeth Glaser Scientist supported by the Elizabeth Glaser Pediatric AIDS Foundation.
PY - 2002/4/1
Y1 - 2002/4/1
N2 - The relative potency and tolerability of multidrug regimens used to treat infants and children infected with human immunodeficiency virus type 1 (HIV-1) are largely unknown. In Pediatric AIDS Clinical Trials Group (PACTG) Protocol 377, 181 infants and children were assigned to receive stavudine (d4T) plus nevirapine (NVP) and ritonavir (RTV); d4T plus lamivudine (3TC) and nelfinavir (NFV); d4T plus NVP and NFV; or d4T plus 3TC, NVP, and NFV. Eleven additional children received d4T and NVP plus NFV given twice daily. All subjects had not previously received protease inhibitors or nonnucleoside reverse-transcriptase inhibitors and all had been immunologically stable while receiving reverse-transcriptase inhibitor therapy. After 48 weeks of therapy, 17 (41%) of 41 subjects receiving d4T-NVP-RTV, 13 (30%) of 44 receiving d4T-NVP-NFV, 21 (42%) of 50 receiving d4T-3TC and NFV (3 times daily), and 22 (52%) of 42 receiving d4T-3TC-NVP-NFV were still receiving their assigned therapy and had HIV-1 RNA suppression to ≤400 copies/mL. These regimens were similar in their drug activity, but the 4-drug regimen offered slightly more durable suppression of viremia.
AB - The relative potency and tolerability of multidrug regimens used to treat infants and children infected with human immunodeficiency virus type 1 (HIV-1) are largely unknown. In Pediatric AIDS Clinical Trials Group (PACTG) Protocol 377, 181 infants and children were assigned to receive stavudine (d4T) plus nevirapine (NVP) and ritonavir (RTV); d4T plus lamivudine (3TC) and nelfinavir (NFV); d4T plus NVP and NFV; or d4T plus 3TC, NVP, and NFV. Eleven additional children received d4T and NVP plus NFV given twice daily. All subjects had not previously received protease inhibitors or nonnucleoside reverse-transcriptase inhibitors and all had been immunologically stable while receiving reverse-transcriptase inhibitor therapy. After 48 weeks of therapy, 17 (41%) of 41 subjects receiving d4T-NVP-RTV, 13 (30%) of 44 receiving d4T-NVP-NFV, 21 (42%) of 50 receiving d4T-3TC and NFV (3 times daily), and 22 (52%) of 42 receiving d4T-3TC-NVP-NFV were still receiving their assigned therapy and had HIV-1 RNA suppression to ≤400 copies/mL. These regimens were similar in their drug activity, but the 4-drug regimen offered slightly more durable suppression of viremia.
UR - http://www.scopus.com/inward/record.url?scp=0036532103&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036532103&partnerID=8YFLogxK
U2 - 10.1086/338814
DO - 10.1086/338814
M3 - Article
C2 - 11880966
AN - SCOPUS:0036532103
SN - 1058-4838
VL - 34
SP - 991
EP - 1001
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 7
ER -
